Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.53 from other evidence | 0.00 |
| cell type Human Protein Atlas | Human Protein Atlas did not answer (Human Protein Atlas: The operation was aborted due to timeout) | 0.00 |
| chemistry Open Targets | compounds already reach it: hexylcaine, propafenone hydrochloride, primidone +70 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 7 Parkinson's papers of 883 | 0.73 |
| pathways Reactome | 3 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 0182
Sealed predictions
- SCN2A in dopamine neurons, braak+0.52 (p 0.150) → +0.23 (p 0.555)receipt 0189
Swarm cases
receipt 0189: SCN2A in dopamine neurons, braak
- power
- full sample +0.34 (p 0.173, n 18), 95% CI -0.16 to +0.69. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.34 (p 0.173, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.31 (p 0.207, n 18). could be the mix.
- skeptic
- leave-one-out range +0.24 to +0.51, sign flips 0; without severely affected donors +0.34 (p 0.173, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SCN2A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts